secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-05-20T20:15:21+00:00
Accession:  0001104659-26-064514
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio prices $15M public offering of 7.9M shares and warrants
-------------------------------------------------------------------

- Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.
- Gross proceeds of ~$15M; expected closing May 21, 2026.
- Warrants exercisable at $2.25 per share, six-year term from issuance.
- Net proceeds for clinical development of buntanetap in Alzheimer's and Parkinson's and working capital.
- Canaccord Genuity acting as sole bookrunner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/0001104659-26-064514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926064514/tm2615162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-064514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer